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Abstract. Background/Aim: Double diagnosis of lung cancer
(LC) and ovarian cancer (OC) is rare. Here, we describe
patients with synchronous/metachronous LC and OC to
identify common clinical and pathological patterns. Patients
and Methods: Clinical, pathological and molecular data of
patients diagnosed and treated at 30 European Institutions
from 2008 to 2018 were retrieved and analysed. Whenever
tissue was available, centralized pathology revision was
performed. Results: A total of 19 cases were found; one was
excluded at pathology revision. Most LCs were
adenocarcinomas (15/18) and most OCs were high-grade
serous (15/18) carcinomas. Of the 9 patients analysed, 7
carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK)
and five out of 7 carried BRCA mutations. One patient with a
germline-BRCA1 mutation received olaparib, resulting in a
durable response of both malignancies. Median overall
survival was 33 months. Conclusion: In our series, most
synchronous/metachronous LCs and OCs showed genetic
alterations. Further analyses with wide NGS panel could shed
light on the biological mechanisms driving their occurrence.
Over the past few decades, lung cancer (LC) diagnoses and
mortality have progressively increased in the female
population. Non-small cell LC (NSCLC) accounts for about
85% of all LC cases and represents the first cause of cancer
death and the third most common cancer in women living in
developed countries (1). In the same context, ovarian cancer
(OC) is the eighth malignancy for incidence and the fifth for
mortality (2).
In advanced stages, despite multidisciplinary management
and treatment combining surgery, chemotherapy and targeted
therapy, prognosis remains poor for both malignancies (2). 
Epidemiological studies and – more recently – molecular
testing have revealed that in the female population NSCLC
could be a biologically distinct entity, due to shared clinical
and molecular features associated with better prognosis (3).
Women affected by NSCLC show a higher incidence of
mutations in the epidermal growth factor receptor (EGFR)
gene, irrespective from being more often never-smokers.
Moreover, whenever these mutations are present, patients
receiving targeted therapy with the highly effective tyrosine-
kinase inhibitors (TKIs) can achieve a longer life expectancy
than the one traditionally obtained with chemotherapy (4). 
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In the OC scenario, the availability of DNA sequencing
technologies had similar implications: the detection of
impairments in genes involved in homologous recombination
repair of DNA breaks (Homologous Recombination
Deficiency, HRD) has identified a subset of patients with
high-grade serous OCs who most likely benefit from treatment
with poly(ADP-ribose) polymerase inhibitors (PARPi).
Germline or somatic loss-of-function mutations in the BReast
CAncer (BRCA) genes are the most common aberrations in
HRD. However, other genomic or post-transcriptional events
can be responsible for HRD (5). As reported by the Cancer
Genome Atlas, almost half of the high-grade serous OC
exhibits HRD (6). On the other hand, even though rare, cases
of HRD have been described also in LC (7).
Despite the increasing incidence of LC, association with
OC is rare and, so far, no literature data are available on this
topic. The aim of this report was to describe a series of
patients with synchronous or metachronous LC and OC and
to identify common clinical and pathological patterns.
Patients and Methods
In this descriptive case series, we retrospectively retrieved the
medical charts of patients referred to 30 Oncological Institutes in
Europe (Italy, France, Slovenia), from 2008 to 2018. 
When patients with history of LC and OC were found, detailed
medical history was recorded including the following pathological
features and clinical outcomes: i) age at first cancer diagnosis; ii)
family history of cancer, smoking habits and hormonal status; iii)
morphological features of LC and OC including tumor histotype,
grade and stage (according to 8th TNM Edition for LC and to the
International Federation of Gynecology and Obstetrics (FIGO) for
OC); iv) timing and types of either local and systemic treatments
received as well as of data regarding treatment initiation and
progression; v) survival information. Median overall survival was
calculated from the date of diagnosis of the first malignancy to the
date of death or date of last follow-up. Whenever tested, genetic
alterations, including germline BRCA (gBRCA) mutations in OC,
were also reported. 
LC and OC were considered synchronous, when the time interval
between disease onsets was shorter than 3 months, whereas for
metachronous we included all the cases of LC and OC that occurred
within a time frame longer than 3 months.
Concerning pathology examination, centralized pathology revision
on cytological or histological formalin fixed paraffin embedded tumor
tissue (FFPE) was performed at the San Luigi Gonzaga Hospital,
where an immunohistochemistry (IHC) marker panel including TTF-
1 and PAX-8 was carried out when necessary. In ambiguous cases, a
broader panel including p40, CK-7, WT1, CA125, Calretinin, EMA,
CEA, CgA, Vimentin, Napsin-A was performed. 
Results
As of May 2018, across the 30 Institutes inquired, we
retrieved 19 cases of synchronous/metachronous LC and OC
in the last 10 years. One patient was excluded, since
centralized pathology revision revealed that the lung lesions
were actually metastases from OC. Thus, 18 patients were
considered eligible for final data analysis. Details of patients’
characteristics are reported in Table I.
In the majority of cases (12/18), LC and OC were
metachronous, with a median time interval between
diagnoses of 6.5 years (range=7 months - 9 years). In the
70.6% of cases, OC preceded LC onset. 
As for medical history, median age at diagnosis of the first
malignancy was 62 years (range=37-79 years); the majority
of patients (61.1%) were never-smokers and 38% had a
family history of cancer. Interestingly, five patients (27.7%)
were diagnosed with a third or fourth malignancy during
their lifetime (1 case of breast cancer, 1 case of lymphoma
and colon cancer, 1 case of small bowel cancer, 1 case of
breast and kidney cancer and 1 case of medullary thyroid
carcinoma).  
In most cases, LC was diagnosed at an early or locally
advanced stage (33.3% for stage I-IIb and 33.3% stage IIIA),
22.2% cases were metastatic. For two patients, LC staging
data were missing. Conversely, at the time of diagnosis, OC
cases were predominantly at advanced stage (50% III-IV). 
Regarding pathology data, all of the LC diagnoses were
performed on the primary tumor lesion. In three cases biopsy
tissue consisted of a cytological specimen from bronco-
alveolar lavage, in four cases of a cyto-histological specimen
from fine (18 Gauge) needle aspiration, in one case of a
histological sample from pleural biopsy and one case is
unknown. In the remaining nine cases, irrespective of the
initial biopsy modality, LC diagnosis was confirmed on
surgical specimens. In all of the OC cases, diagnosis was
confirmed on surgical specimens. Paired specimens of both
primary tumors were available in seven cases.
Regarding histology, 83.3% of LC were adenocarcinoma
and 83.3% of OC were high-grade serous carcinoma. 
Twelve patients underwent molecular screening for LC
oncogene drivers. Of them, 58.3% showed oncogene-addicted
lung disease: four cases were EGFR mutant, one B-RAF-V600
mutant and two had EMLA4-ALK rearrangement. Testing for
gBRCA status was performed in seven cases: three had
mutations (2 BRCA2 and 1 BRCA1), two were wild-type and
two carried variants of unknown significance (VUS).
Remarkably, one synchronous case of lung and ovarian
carcinoma presented both a BRCA-VUS and a B-RAF-V600
mutation at the lung site.
As for treatment, consistent with disease stage at
diagnosis, most cases of OC underwent primary de-bulking
surgery as frontline therapy (14/18, 77.7%), whereas for LC,
lobectomy was performed in eight cases (44.4%). Of the
remaining LC cases, four were treated with platinum-based
chemotherapy, four received a TKI and two chemo-
radiotherapy. Regarding OC, all patients received platinum-
based chemotherapy, either in adjuvant or first-line setting.
Remarkably, one patient with synchronous advanced
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ovarian and lung adenocarcinoma (both in stage IIIA at
diagnosis and radically resected) carrying a germline BRCA1
mutation had a durable partial response of both cancers
following olaparib treatment for relapse. Ovarian cancer
relapse was diagnosed with computed tomography (CT) and
positron emission tomography (PET) where increased
metabolic activity was detected in interaortocaval and lombo-
aortic lymph nodes, along with an increase in CA-125 levels;
lung cancer relapse was diagnosed as increased metabolic
activity in mediastinal and supraclavicular lymph nodes, with
an increase in the levels of CEA and CA 19.9 markers.
At the time of data analysis, after a median follow-up of
6.8 years, median overall survival was 33 months (95%
confidence interval (IC)=1.98-55.5)) and 11 patients are still
alive (Figure 1). 
Two examples of the pathological revisions performed in
this study are provided in Figures 2 and 3.
Discussion
In this report, we showed that patients who develop double
LC and OC primaries share common clinical and
pathological features. Notably, in most cases either LC or
OC had an underlying molecular alteration. Across the
patients who underwent molecular testing for LC, 58.3%
showed oncogene-addicted disease. Similarly, of the seven
cases tested for BRCA, five showed abnormalities. Moreover,
even in cases carrying an unknown variant or were negative
for a BRCA mutation, individual history of other associated
malignancies or a family history of cancer were observed
(2/4 cases and 3/5 cases, respectively). 
HRD has been described also in LC, but the overall
incidence of germline BRCA mutations in NSCLC is
unknown. Among the little available evidence, an interesting
perspective is provided by a small report on two EGFR
mutant NSCLC male patients, whose family history for
breast and OC led to the detection of a gBRCA2 mutation in
both cases. The authors, to investigate if genetic
susceptibility to DNA repair defects could predispose to the
development of EGFR mutant tumors, screened 110 Jewish
patients with lung cancer and found that three harbored
gBRCA mutations (2.7%). They further screened 13
Ashkenazi Jewish patients with EGFR mutant NSCLC and
found that none had gBRCA1/2 mutations (8).
However, in contrast to defects caused due to a single
genomic mutation, as in the case of BRCA mutations, DNA
repair in LC seems to be more often affected at the epigenetic
level. It has been reported that epigenetic alterations combined
with reduced mRNA and protein expression levels of BRCA1
occur in up to 44% of NSCLC, through various mechanisms,
such as promoter hypermethylation (7). For example, low
expression of ERCC1 was shown in 56% of cases of a large
cohort of NSCLC patients, whereas PTEN mutations have
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Figure 1. Overall survival in our case-series: median overall survival
was 33 months (95%CI=1.98-55.5).
Table I. Characteristics of the study population.
Patients number                                                                18
Median age at first diagnosis (years, range)                  62 (37-79)
Smoking habit
   Never-smoker                                                               11 (61.1%)
   Former-smoker                                                               4 (22.2%)
   Current-smoker                                                              2 (11.1%)
   Unknown                                                                       1 (5.5%)
Cancer familial history
   Yes                                                                                  7 (38.8%)
   No/unknown                                                                 11 (61.1%)
Synchronous LC and OC                                                  6 (33.3%)
Metachronous LC and OC                                              12 (66.7%)
Median time interval between 
LC and OC diagnoses (years, range)                                4.5 (0.7-9)
LC histology
   Adenocarcinoma                                                          15 (83.3%)
   Squamous                                                                       2 (11.1%) 
   Small cell lung cancer                                                   1 (5.5%)
OC histology
   High-grade serous                                                        15 (83.4%)
   Endometrioid                                                                  1 (5.5%)
   Mucinous                                                                        2 (11.1%)
LC stage (TNM 8th edition)
   I-IIa                                                                                 6 (33.3%)
   IIIa                                                                                  6 (33.3%)
   IIIb-IV                                                                            4 (22.2%)
   Unknown                                                                        2 (11.2%)
OC stage (FIGO)
   IC                                                                                    7 (38.9%)
   III                                                                                    7 (38.9%)
   IV                                                                                    2 (11.1%)
   Unknown                                                                        2 (11.1%)
Median follow-up (years, range)                                       6.8 (1-15)
Median overall survival (months, 95%CI)                     33 (1.98-55.5)
been reported in 9% of NSCLC patients where they confer
higher sensitivity to PARPi (7-9).
As for the implications on treatment outcome of patients
with EGFR-mutant NSCLC, at least two studies showed that
high BRCA1 mRNA expression was associated with shorter
progression-free survival when patients received erlotinib
(10-11). This evidence provided the rationale for a
combination trial of the anti-EGFR TKI, gefitinib, plus the
PARPi olaparib (12). This subgroup of NSCLC patients with
an HR dysfunction constitutes a rare population which may
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Figure 2. Immunohistochemistry images from specimens obtained from Patient 1 representing (A) lung primary TTF-1 and (B) lung metastasis PAX-
8. MF, Never smoker, 78 years old at the time of diagnosis of lung adenocarcinoma, EGFR mutated on exon 21, IV stage. She received afatinib as
1st line treatment. Twenty-nine months later, disease progression with new brain and lung lesions, for which she underwent a re-biopsy on a lung
metastasis, showing an undifferentiated malignancy with loss of EGFR mutation, TTF-1 (-). One month later, onset of a pelvic mass, at the ago-
biopsy poor differentiated ovarian carcinoma, PAX-8 (+), ER 10%. Patient died two months later. At the pathology revision, the lung metastasis
was revealed to be a secondary lesion from the ovarian carcinoma (see Figure 1B).
Figure 3. Immunohistochemistry images from specimens obtained from Patient 2 representing (A) lung primary H/E and (B) ovarian primary H/E.
GU, Never smoker, 51 years old at the time of diagnosis of lung adenocarcinoma, EGFR and KRAS wild type. Lung disease at stage I, thus an
upper left lobectomy was performed. Three months later, onset of a pelvic mass, involving both uterus and left ovary. At the pathological examination,
synchronous endometrioid carcinoma of the uterus and the ovary was diagnosed. Following hystero-annessiectomy, patient underwent adjuvant
chemotherapy. Three years later, the patient developed breast cancer and BRCA examination was performed, revealing a BRCA2 mutation of
unknown significance. Patient died one year later.
also be sensitive to treatment with PARPi. So far, it is
unknown if this phenotype occurs only at the somatic level
in cancer cells or, in a few cases, may also reflect a germline
pattern. In our case series, whole exome sequencing was not
carried out, so we can only speculate that at least in some of
the cases described, the association of LC and OC was
driven by an underlying common germline alteration in the
DNA repair machinery.
This study has certain limitations. It is a retrospective
study, with missing clinical data and limited availability of
paired histological specimens. In many instances, molecular
testing for LC oncogene drivers and for BRCA status in OC
was not performed, in part due to the extended time frame
of the study – as the recommendations for molecular testing
considerably changed along the 10 years covered in this
case-series – and in part for the lack of a family history
suggestive for a BRCA mutation or because of the early
TNM stage at the time of LC diagnosis. In this respect, it is
worth to notice that many LC cases were diagnosed at early
stages, probably because the lung lesions were detected as
occasional radiological findings along the follow-up for the
preceding OC. This could also explain the long survival time
observed in this case series. 
Beyond the findings and the limitations mentioned above,
our report – which represents the largest patients’ series of
associated LC and OC – also outlines the clinical and
pathologic diagnostic challenge of distinguishing secondary
from primary ovarian neoplasms. This is true especially in
the presence of synchronous tumors, where imaging
techniques and conventional morphology alone may be often
inadequate to obtain a reliable diagnosis.
In our report, the use of appropriate IHC markers in the
pathology workup revealed that, in one case, the lung lesions
deemed as primary lung adenocarcinoma were actually
metastases from OC. It is worth mentioning that at the time
of initial diagnosis, the biopsy specimen consisted of pleural
cytology, which can often be misleading. 
Lung represents the second preferential metastatic site for
ovarian cancer (28.4% across 819 distant metastatic sites
examined from SEER database) and, when present, has
negative prognostic value (13). On the other hand, ovarian
metastases from LC represent only 0.4-1.0% of all ovarian
metastatic masses (14-16). However, such frequency is likely
to increase due to the rising incidence of lung cancer in
women (1). Surprisingly, several reports have described
cases of ovarian metastases from lung adenocarcinoma
associated with driver EGFR mutations, and even more
commonly, with ALK rearrangements (17).
In conclusion, our study represents the largest case series
of double LC and OC primaries, that not only underlines the
key role of IHC in the differential diagnosis of metastatic
disease, but also identifies common clinical and pathological
features, with many cases driven by genetic alterations. As a
future perspective, further analyses using an NGS panel
could shed light on the biological mechanisms driving the
occurrence of concomitant LC and OC, with beneficial
repercussions on prevention and treatment strategies.
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